New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareBronchogen vs GHK

Bronchogen vs GHK

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Bronchogen
Skin & CosmeticAnti-Aging & Longevity
GHK
Summary
Bronchogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Leu) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is a tissue-specific bioregulator designed for the bronchi and lungs, promoting normalization of bronchial epithelial cell function. Research suggests benefits for respiratory health, protection against pulmonary aging, and support for bronchopulmonary conditions.
GHK is the natural tripeptide (Gly-His-Lys) released from human albumin that activates tissue remodeling, collagen synthesis, and anti-aging gene expression. The copper-free form is the biological signaling molecule; it chelates copper in tissue to form GHK-Cu but also has independent biological activity.
Half-Life
Short (minutes to hours); bioregulator effects are gene-mediated and longer lasting
Extremely short as free peptide; tissue binding extends local effects
Admin Route
SubQ, Oral
SubQ, Topical, Oral
Research
Typical Dose
10 mg per day
100–500 mcg
Frequency
Daily for 10–30 days
Daily or 5x per week
Key Benefits
  • Tissue-specific support for bronchial and lung health
  • Promotes normalization of bronchial epithelial cell function
  • Potential benefits in chronic bronchitis and COPD support
  • Anti-aging effects on pulmonary tissue
  • May reduce frequency of respiratory infections
  • Supports lung function preservation with aging
  • Compatible with other Khavinson bioregulator peptides
  • Stimulates collagen and extracellular matrix synthesis
  • Activates tissue repair gene expression programs
  • Anti-aging: reverses 57% of age-related gene changes
  • Antioxidant and anti-inflammatory
  • Wound healing and skin barrier repair
  • Improves skin laxity, texture, and radiance
  • Neuroprotective (stimulates NGF, BDNF)
  • Anti-fibrotic in liver and lung models
Side Effects
  • Generally well tolerated in research studies
  • Mild local reactions at injection site (if injected)
  • No significant systemic side effects reported at standard doses
  • Excellent safety profile (naturally occurring peptide)
  • Rare: mild injection site reaction (SC)
  • No significant adverse effects identified in research
Stacks With